John Monahan
Director/Board Member bei SCORPIUS HOLDINGS, INC.
Vermögen: 12 $ am 31.03.2024
Profil
John James Monahan is the founder of Avigen, Inc. (founded in 1992) and Tacere Therapeutics, Inc. (founded in 2006).
He held the position of Chief Executive Officer at Avigen, Inc. from 1992 to 2004 and was a Director at Tacere Therapeutics, Inc. from 2006 to 2012.
Currently, he is a Director at Elusys Therapeutics, Inc., Cellix Ltd., Spark Therapeutics Ireland Ltd., and Luxcel Biosciences Ltd.
He is also an Independent Director at Scorpius Holdings, Inc. (since 2009), Theriva Biologics, Inc. (since 2020).
He was the Lead Independent Director at Anixa Biosciences, Inc. from 2016 to 2021.
He was a Director at GK Technologies, Inc. and IdentiGEN Ltd.
He held the position of Vice President-Research & Development at Somatix Therapy Corp.
from 1989 to 1992 and was the Group Chief-Molecular Genetics at Hoffmann-La Roche, Inc. from 1982 to 1985.
He was a Director-Molecular & Cell Biology at Triton Biosciences, Inc. from 1985 to 1989 and a Director at Trino Therapeutics Ltd.
from 1985 to 1989.
He received his doctorate degree from McMaster University in 1974 and his undergraduate degree from University College Dublin in 1969.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
SCORPIUS HOLDINGS, INC.
0,00% | 18.08.2023 | 73 ( 0,00% ) | 12 $ | 31.03.2024 |
THERIVA BIOLOGICS, INC.
-.--% | 25.03.2024 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von John Monahan
| Unternehmen | Position | Beginn |
|---|---|---|
| SCORPIUS HOLDINGS, INC. | Director/Board Member | 01.11.2009 |
| THERIVA BIOLOGICS, INC. | Director/Board Member | 11.11.2020 |
Luxcel Biosciences Ltd.
 Luxcel Biosciences Ltd. Medical SpecialtiesHealth Technology Luxcel Biosciences Ltd. develops, manufactures, and distributes optical fluorescence test solutions for application in the pharmaceutical and food safety industries. It offers MitoXpress Xtra oxygen consumption assay, MitoXpress stress test, MitoXpress FAO assay, pH-Xtra Glycolysis assay, and pH-Xtra Glycolysis stress test. The company was founded by Richard Fernandes and Dmitri Papkovsky in 2002 and is headquartered in Cork, Ireland. | Director/Board Member | - |
Spark Therapeutics Ireland Ltd.
 Spark Therapeutics Ireland Ltd. Pharmaceuticals: MajorHealth Technology Spark Therapeutics Ireland Ltd. develops new gene medicines to treat autosomal dominant genetic diseases. Its product RhoNova, is designed for the treatment of patients with rhodopsin linked autosomal dominant retinitis pigmentosa, a debilitating, progressive form of inherited blindness resulting from a diverse array of mutations in the RHO gene. The company was founded by Jane G. Farrar, Paul Kenna, and Gearóid Tuohy and is headquartered in Dublin, Ireland. | Director/Board Member | 06.09.2011 |
Cellix Ltd.
 Cellix Ltd. Medical SpecialtiesHealth Technology Cellix Ltd. develops microfluidic pumping solutions, consumable biochips, software, and automated solutions. It offers its solutions for applications in cell biology, microfluidics and nanofluidics, physics, chemistry, cell, and particle studies. The company was founded by Dmitry Kashanin, Vivienne Williams, Francis Odowd, and Igor Shvets in 2004 and is headquartered in Dublin, Ireland. | Director/Board Member | 24.09.2009 |
Elusys Therapeutics, Inc.
 Elusys Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elusys Therapeutics, Inc. develops antibody therapies. It is engaged in development Anthim (oblitoxaximab) a mAb anthrax antitoxin for the treatment and prevention of inhalational anthrax used in a bioterror attack. The company was founded in May 1998 and is headquartered in Pine Brook, NJ. | Director/Board Member | - |
Ehemalige bekannte Positionen von John Monahan
| Unternehmen | Position | Ende |
|---|---|---|
| ANIXA BIOSCIENCES, INC. | Director/Board Member | 21.05.2021 |
Tacere Therapeutics, Inc.
 Tacere Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tacere Therapeutics, Inc. provides treatment of infectious diseases. It develops novel therapeutics for the treatment of serious infectious diseases such as Hepatitis C (HCV). The company was founded by Sara M. Hall, Amit J. Kumar, John James Monahan, and Michael J. Catelani in 2006 and is headquartered in San Jose, CA. | Founder | 01.01.2012 |
Avigen, Inc.
 Avigen, Inc. Medical SpecialtiesHealth Technology Avigen, Inc. produces and sells drugs, animal health products, and chemicals. The firm also develops and commercializes small molecules of therapeutics and biologics for use in the treatment of serious neurological and neuromuscular disorders. The company was founded in 1992 and is headquartered in La Jolla, CA. | Chief Executive Officer | 01.03.2004 |
| ░░░░░░░ ░░░░░░░ ░░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | - |
| ░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Ausbildung von John Monahan
| McMaster University | Doctorate Degree |
| University College Dublin | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| ANIXA BIOSCIENCES, INC. | Health Technology |
| SCORPIUS HOLDINGS, INC. | Health Technology |
| THERIVA BIOLOGICS, INC. | Health Technology |
| Private Unternehmen | 12 |
|---|---|
Somatix Therapy Corp.
 Somatix Therapy Corp. BiotechnologyHealth Technology Somatix Therapy Corp. researches, develops, and commercialize proprietary processes for the genetic modification of cells and their use in the treatment of human disease. Somatix's assets include its highly efficient gene transfer technology, broad-based intellectual property, and focused product development programs. The company's most advanced clinical development program, the GVAX cancer vaccine, is in Phase I/II clinical trials for the treatment of metastatic renal cell carcinoma, advanced melanoma, and prostate cancer. It is located in Alameda, CA | Health Technology |
Avigen, Inc.
Avigen, Inc. Medical SpecialtiesHealth Technology Avigen, Inc. produces and sells drugs, animal health products, and chemicals. The firm also develops and commercializes small molecules of therapeutics and biologics for use in the treatment of serious neurological and neuromuscular disorders. The company was founded in 1992 and is headquartered in La Jolla, CA. | Health Technology |
GK Technologies, Inc.
 GK Technologies, Inc. Metal FabricationProducer Manufacturing GK Technologies, Inc. manufactures wire and cable products, electronic and electrical circuit components, and environmental products. The company is headquartered in Woodcliff Lake, NJ. | Producer Manufacturing |
Elusys Therapeutics, Inc.
Elusys Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elusys Therapeutics, Inc. develops antibody therapies. It is engaged in development Anthim (oblitoxaximab) a mAb anthrax antitoxin for the treatment and prevention of inhalational anthrax used in a bioterror attack. The company was founded in May 1998 and is headquartered in Pine Brook, NJ. | Health Technology |
IdentiGEN Ltd.
 IdentiGEN Ltd. Miscellaneous Commercial ServicesCommercial Services IdentiGEN Ltd. provides DNA-based food tracking and labeling solutions to the agri-food industry. The company was founded by Ciaran Meghen, Ronan Loftus, and Patrick J. Cunningham in 1996 and is headquartered in Dublin, Ireland. | Commercial Services |
Tacere Therapeutics, Inc.
Tacere Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tacere Therapeutics, Inc. provides treatment of infectious diseases. It develops novel therapeutics for the treatment of serious infectious diseases such as Hepatitis C (HCV). The company was founded by Sara M. Hall, Amit J. Kumar, John James Monahan, and Michael J. Catelani in 2006 and is headquartered in San Jose, CA. | Health Technology |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Health Technology |
Cellix Ltd.
Cellix Ltd. Medical SpecialtiesHealth Technology Cellix Ltd. develops microfluidic pumping solutions, consumable biochips, software, and automated solutions. It offers its solutions for applications in cell biology, microfluidics and nanofluidics, physics, chemistry, cell, and particle studies. The company was founded by Dmitry Kashanin, Vivienne Williams, Francis Odowd, and Igor Shvets in 2004 and is headquartered in Dublin, Ireland. | Health Technology |
| Triton Biosciences, Inc. | |
Spark Therapeutics Ireland Ltd.
Spark Therapeutics Ireland Ltd. Pharmaceuticals: MajorHealth Technology Spark Therapeutics Ireland Ltd. develops new gene medicines to treat autosomal dominant genetic diseases. Its product RhoNova, is designed for the treatment of patients with rhodopsin linked autosomal dominant retinitis pigmentosa, a debilitating, progressive form of inherited blindness resulting from a diverse array of mutations in the RHO gene. The company was founded by Jane G. Farrar, Paul Kenna, and Gearóid Tuohy and is headquartered in Dublin, Ireland. | Health Technology |
Luxcel Biosciences Ltd.
Luxcel Biosciences Ltd. Medical SpecialtiesHealth Technology Luxcel Biosciences Ltd. develops, manufactures, and distributes optical fluorescence test solutions for application in the pharmaceutical and food safety industries. It offers MitoXpress Xtra oxygen consumption assay, MitoXpress stress test, MitoXpress FAO assay, pH-Xtra Glycolysis assay, and pH-Xtra Glycolysis stress test. The company was founded by Richard Fernandes and Dmitri Papkovsky in 2002 and is headquartered in Cork, Ireland. | Health Technology |
Trino Therapeutics Ltd.
 Trino Therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Trino Therapeutics Ltd. operates as a drug discovery and development company. It focuses on developing oral small molecules for the treatment and unmet management of inflammatory bowel disease and other inflammatory indications. The company was founded by Neil Howard Frankish and Helen Sheridan in 1999 and is headquartered in Dublin, Ireland. | Health Technology |
